Summary
SUMOMyePath: a New Pathway to Wrestle Demyelinating diseases.
(Re)myelination is the process by which Oligodendrocyte Precursor Cells (OPCs) migrate and differentiate and mature into myelin generating Oligodendrocytes (OLs). Understanding this process is key to cure demyelinating disorders of which, Multiple Sclerosis (MS), is the most prevalent, affecting 2.8 million individuals worldwide and specially women (69%). SUMOylation is a post-translational modification mainly studied in neurons within the central nervous system, however its pathway’s role in oligodendroglia and its relation with myelin (patho)physiology remains to be investigated. Thus, it is an exciting field to explore and SUMOMyePath will address this challenge by synergizing the applicant’s experience in SUMOylation and myelin biology and the expertise of 1) the host group´s (UniTo) in OPCs biology and 2) the secondment group´s (Ubx) in state-of-art live-imaging of OL lineage cells, opening novel avenues of research and, as consequence, new diagnostic and therapeutic strategies.
(Re)myelination is the process by which Oligodendrocyte Precursor Cells (OPCs) migrate and differentiate and mature into myelin generating Oligodendrocytes (OLs). Understanding this process is key to cure demyelinating disorders of which, Multiple Sclerosis (MS), is the most prevalent, affecting 2.8 million individuals worldwide and specially women (69%). SUMOylation is a post-translational modification mainly studied in neurons within the central nervous system, however its pathway’s role in oligodendroglia and its relation with myelin (patho)physiology remains to be investigated. Thus, it is an exciting field to explore and SUMOMyePath will address this challenge by synergizing the applicant’s experience in SUMOylation and myelin biology and the expertise of 1) the host group´s (UniTo) in OPCs biology and 2) the secondment group´s (Ubx) in state-of-art live-imaging of OL lineage cells, opening novel avenues of research and, as consequence, new diagnostic and therapeutic strategies.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101106517 |
| Start date: | 01-04-2024 |
| End date: | 31-03-2026 |
| Total budget - Public funding: | - 188 590,00 Euro |
Cordis data
Original description
SUMOMyePath: a New Pathway to Wrestle Demyelinating diseases.(Re)myelination is the process by which Oligodendrocyte Precursor Cells (OPCs) migrate and differentiate and mature into myelin generating Oligodendrocytes (OLs). Understanding this process is key to cure demyelinating disorders of which, Multiple Sclerosis (MS), is the most prevalent, affecting 2.8 million individuals worldwide and specially women (69%). SUMOylation is a post-translational modification mainly studied in neurons within the central nervous system, however its pathway’s role in oligodendroglia and its relation with myelin (patho)physiology remains to be investigated. Thus, it is an exciting field to explore and SUMOMyePath will address this challenge by synergizing the applicant’s experience in SUMOylation and myelin biology and the expertise of 1) the host group´s (UniTo) in OPCs biology and 2) the secondment group´s (Ubx) in state-of-art live-imaging of OL lineage cells, opening novel avenues of research and, as consequence, new diagnostic and therapeutic strategies.
Status
SIGNEDCall topic
HORIZON-MSCA-2022-PF-01-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
Search
